Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
Status:
Terminated
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
This study will be conducted in a single center, double-blind with 6 dose escalation groups
to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of
BAY1161116.